Morgan Stanley upgraded Sanofi (SNY) to Overweight from Equal Weight with a price target of $58, up from $56. The firm believes the recent pullback in the shares brings an attractive entry point. The clarity on amlitelimab removes an overhang on the stock, and the equity story can shift from research and development execution back to Sanofi’s earnings momentum in the near-term, the analyst tells investors in a research note. Morgan Stanley believes margin expansion in 2026 now looks possible for the company, supported by continued sales momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Sanofi Stock (SNY) Revives after Trial Miss as Analyst Hails ‘Buying Opportunity’
- Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher
- Sanofi’s Amlitelimab Shows Promising Results in Atopic Dermatitis Study
- Piper says competitor AD data reinforces Nektar’s REZPEG differentiated profile